New transfer of care initiative of electronic referral from hospital to community pharmacy in England : a formative service evaluation. by Nazar,  H. et al.
Durham Research Online
Deposited in DRO:
03 August 2016
Version of attached ﬁle:
Accepted Version
Peer-review status of attached ﬁle:
Peer-reviewed
Citation for published item:
Nazar, H. and Brice, S. and Akhter, N. and Kasim, A. and Gunning, A. and Slight, S.P. and Watson, N.
(2016) 'New transfer of care initiative of electronic referral from hospital to community pharmacy in England :
a formative service evaluation.', BMJ open., 6 (10). e012532.
Further information on publisher's website:
https://doi.org/10.1136/bmjopen-2016-012532
Publisher's copyright statement:
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC
BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and
license their derivative works on diﬀerent terms, provided the original work is properly cited and the use is
non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Additional information:
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for
personal research or study, educational, or not-for-proﬁt purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in DRO
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full DRO policy for further details.
Durham University Library, Stockton Road, Durham DH1 3LY, United Kingdom
Tel : +44 (0)191 334 3042 | Fax : +44 (0)191 334 2971
http://dro.dur.ac.uk
 1 
 
Title: A new Transfer of Care initiative of electronic referral from hospital to community 
pharmacy in England: A formative service evaluation 
 
Corresponding author: Hamde Nazar, School of Medicine, Pharmacy and Health, Durham 
University, Queen’s Campus, Stockton-On-Tees, TS17 6BH, UK, 
hamde.nazar@durham.ac.uk, 00441913340250 
 
Steven Brice, Pharmacy Department, Newcastle-upon-Tyne NHS Foundation Trust, 
Newcastle-upon-Tyne, UK 
 
Nasima Akhter, Wolfson Research Institute for Health and Wellbeing, Durham University, 
Queen’s Campus, Stockton-On-Tees, UK 
 
Adetayo Kasim, Wolfson Research Institute for Health and Wellbeing, Durham University, 
Queen’s Campus, Stockton-On-Tees, UK 
 
 
Ann Gunning, Head of Services and Support North of Tyne Local Pharmaceutical 
Committee, Newcastle-upon-Tyne, UK 
 
 
Sarah P. Slight, School of Medicine, Pharmacy and Health, Durham University, Stockton-
On-Tees, UK 
 
Neil Watson, Pharmacy Department, Newcastle-upon-Tyne NHS Foundation Trust, 
Newcastle-upon-Tyne, UK 
 
Key words: care transitions, health boundaries, information transfer, continuity of care  
 
 
Word count: 4,500  
 
 
 
 
 
 2 
 
 
 
ABSTRACT  
Objectives To evaluate an electronic patient referral system from one UK hospital Trust to 
community pharmacies across the North East of England. 
Setting Two hospital sites in Newcastle-upon-Tyne and 207 community pharmacies. 
Participants In-patients who were considered to benefit from on-going support and 
continuity of care after leaving hospital.  
Intervention Electronic transmission of a patient’s medicines-related information to their 
nominated community pharmacy. Community pharmacists to provide a follow-up 
consultation tailored to the individual patient needs. 
Primary and secondary outcomes Number of referrals made to and received by different 
types  of pharmacies; reasons for referrals; accepted/completed and rejected referred rates; 
reasons for rejections by community pharmacists; time to action referrals; details of the 
follow-up consultations; readmission rates at 30, 60 and 90 days post referral and number 
of hospital bed days. 
Results 2,029 in-patients were referred over a 13-month period (1st July 2014-31st July 
2015). Only 31% (n=619) of these patients participated in a follow-up consultation; 47% 
(n=955) of referrals were rejected by community pharmacies with the most common reason 
being ‘patient was uncontactable’ (35%, n=138). Most referrals were accepted/completed 
within 7 days of receipt and most rejections were made more than 2 weeks after referral 
receipt. Most referred patients were over 60 years old and referred for a Medicines Use 
Review (MUR) or enrolment for the New Medicines Service (NMS). Those patients who 
received a community pharmacist follow-up consultation had statistically significant lower 
rates of readmissions and shorter hospital stays than those patients without a follow-up 
consultation. 
Conclusions Hospital pharmacy staff were able to utilise an IT platform to improve the 
coordination of care for patients transitioning back home from hospital. Community 
pharmacists were able to contact the majority of patients and results indicate that patients 
receiving a follow-up consultation may have lower rates of readmission and shorter hospital 
stays. 
 
ARTICLE SUMMARY 
Strengths and limitations of the study 
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● This study provides a detailed description of how an electronic referral system 
between hospital and community pharmacies across the North East of England was 
implemented. 
● This study demonstrates that in-patients can be effectively referred to their 
nominated community pharmacist and receive a follow-up consultation tailored to 
their needs after discharge from the hospital. 
● The study demonstrates that routine data collection during this evaluative period 
requires critical analysis and additional qualitative work to understand fully the 
operational and implementation aspects of the service, e.g. complex reasons for the 
recorded rates of non-completion of referrals. 
● There is no routinely recorded data at the community pharmacist follow-up 
consultation to allow specific economic, clinical or humanistic outcomes to be 
determined. However, service continual improvements are being made towards 
achieving this. 
● A well-structured clinical trial of this intervention is required to investigate the 
impact on patients as they transition between healthcare settings. 
 
 
INTRODUCTION 
The continuity of patient care when transitioning from one healthcare setting to another is a 
national priority. [1] A range of interventions have been designed, trialled, and tested to 
improve the quality and safety of this transfer process. [2-6] Successful interventions have 
incorporated activities such as medication reconciliation; quick, clear and structured 
discharge summaries; discharge planning; follow-up between hospital and community 
providers; electronic discharge notifications; and Web-based access to discharge 
information for general practitioners. [7] In the design of such interventions, community 
pharmacists have been recognised as accessible and valuable contact points for patients in 
primary care to provide additional advice and counselling, particularly on medication-
related issues and the management of chronic conditions. [8-11] A recent systematic review 
highlighted how community pharmacists could help identify and rectify medication errors, 
thus providing a significant impact on improving outcomes.[8] These community pharmacy 
interventions included activities to improve the quality of information; coordination of care 
and communication between care settings. [8] Other reported outcomes that could be 
realised include: improved patient understanding of their medication and condition, [5, 12] 
improved communication of accurate medication-related information between care 
settings,[5] and the potential to reduce morbidity and mortality associated with targeted 
conditions. [11, 13]  
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In 2012, the Royal Pharmaceutical Society (RPS) issued professional guidance in its 
publication ‘Keeping patients safe when they transfer between care providers – getting the 
medicines right’ on the core principles that underpin the safe transfer of medicines-related 
information for a patient transferring between care providers in any setting. [14] Hospital 
and community sites across the United Kingdom (UK) have adopted this guidance by 
designing services and initiatives to specifically improve patient transitions. In a subsequent 
report, [15] thirty early adopter sites provided information to the RPS on their service 
designs; the barriers they faced; their results and how the initiatives will sustain change and 
facilitate good practice locally going forward.  Of these sites, half incorporated a specific role 
for community pharmacists within their transfer of care programmes, [15] and three were 
used as exemplar case studies by the RPS in their most recent toolkit [16] to support 
hospital referral services to community pharmacy. This document was issued to aid 
commissioners and pharmacy leaders to design and implement an effective referral system. 
[16] However, despite the valuable structure and support this document provided at an 
aerial level, no evaluation has been conducted of a transfer of care initiative incorporating 
active involvement of community pharmacists since the RPS professional guidance was 
issued.[14] We evaluated the Transfer of Care initiative in the North East of England and 
North Cumbria and present aspects of its achievement from two specific hospital sites 
where the initiative has been delivered for the longest period of time and generated the 
most service activity data.  
 
METHODS 
Description of the service intervention  
The transfer of care initiative, the first of its kind in the UK, was launched in July 2014. It was 
a collaborative project between Newcastle-upon-Tyne NHS Foundation Trust, North of Tyne 
Local Pharmacy Committee (LPC) and Pinnacle Health Partnership LLP (provider of 
PharmOutcomes). PharmOutcomes is a web-based platform routinely used by community 
pharmacies in the North East and North Cumbria to record data on service provision. The 
three parties involved in the collaboration created new hospital and community pharmacy 
referral templates within PharmOutcomes to facilitate a secure method of electronic 
transfer of medicines-related information between hospital and community pharmacies. 
[16] Hospital pharmacy staff were shown how to use PharmOutcomes by senior pharmacy 
staff and two launch events were organised for  hospital and community pharmacy staff to 
both inform and answer any questions about the electronic patient referral process. 
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Community pharmacy staff were also provided with further information in both paper-
based and electronic forms, and screenshots to help visualise the content of information 
that would be received by the community pharmacists. Newcastle-upon-Tyne Hospitals 
were the first hospitals to make electronic referrals to community pharmacies and it is their 
service that has been analysed, however following creation of an Academic Health Science 
Network (AHSN) Transfer of Care initiative (October 2014), eight other hospitals in the 
North East and North Cumbria are now also making referrals using PharmOutcomes. The 
service intervention has been described in further detail using the Template for Intervention 
Description and Replication (TIDier) checklist and guide (See Supplemental File 1). [17] Since 
its conception the service has been developed and the changes have been itemised (See 
Supplemental File 2). These will be referred to as findings are discussed. 
 
Referrals sent from the hospital system  
Hospital pharmacy staff, which includes pharmacy technicians and clinical pharmacists 
(approximately n=30 across the two hospital sites) identified patients who, in their clinical 
judgement, would benefit from a follow-up consultation with a community pharmacist. 
These included patients who were on 4 or more medicines or had a number of medicines 
changed during their hospital stay. These patients were approached, informed about the 
service and asked if they would like to participate and nominate a community pharmacy of 
their choice. At the time of the patient’s discharge, a member of hospital pharmacy staff 
(both pharmacists and clinical technicians) would (a) log into PharmOutcomes , (b) populate 
various patient demographic fields including name; date of birth; postcode; ethnicity; NHS 
number; GP details, (c) select a community pharmacy (nominated by the patient) from a 
drop down list, and (d) recommend what additional pharmaceutical service, advice or 
general care might be useful for the patient at the follow-up consultation (‘Reason for 
referral’ field). Finally, the contact details of the member of staff making the referral were 
also recorded.  
 
Referrals received by the community pharmacy system 
Community pharmacists could participate on a voluntary basis, as no contractual or service 
reimbursement arrangements were made. Community pharmacists had the choice of either 
‘accepting’ or ‘rejecting’ the referral sent from the hospital. From December 2014 if a 
referral was rejected, the community pharmacist was prompted to provide a reason from 
the drop down list, which included ‘Housebound patient’, ‘uncontactable patient’, and 
‘other’. If ‘other’ was selected, then further details were required in the free text box 
provided. The drop down list was changed in June 2015 to increase the options available 
and to force the selection of a reason for rejection, removing ‘Housebound patient’ as the 
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default. Alternatively, the community pharmacist could choose to ‘accept’ the referral and 
thus contacted the patient to arrange a follow-up consultation. Further details on what 
medication-related questions were asked to the patient during the consultation were 
collected e.g., Was the patient’s understanding of how to take medications checked? Has 
the patient experienced an adverse drug reaction (ADR)? Any pharmaceutical service(s) that 
were provided to the patient needed to be recorded by the pharmacist e.g., Medicines Use 
Review (MUR) or stop smoking service, as well as any support service(s) e.g., medicines 
reconciliation or review of a compliance aid. Once the consultation had been completed, the 
pharmacist was required to enter further details in PharmOutcomes under the section 
‘Complete the referral’. These details included: name and address of the community 
pharmacy; name and professional registration number of the community pharmacist; the 
reported long-term condition(s) of the patient (cardiovascular disease; respiratory; diabetes 
and other). If a community pharmacist had not acknowledged the referral in 
PharmOutcomes nor registered any action taken, then the status of that referral remained 
recorded as ‘Referred (no action)’ on the system. Data on community pharmacy activity was 
captured through PharmOutcomes.  
 
Data Collection 
Service Activity data 
We evaluated this service from 1st July 2014 – 31st July 2015. All patient identifiable 
information was removed; however, patient age; ethnicity and postcode were included. The 
reasons for referrals by hospital staff, the details of the community pharmacies to which 
referrals were sent, and the subsequent acceptance/rejection and completion rate of these 
referrals were extracted. Community pharmacies were categorised by type: national large 
chain multiple; small regional chain multiple; supermarket pharmacy and independent 
pharmacy. The referral history was tracked to investigate how many referrals were 
actioned, i.e. ‘accepted’, ‘completed’ or ‘rejected’ within 7 days; 7-14 days; and more than 
14 days. Where referrals were rejected, the reasons provided were collated and analysed. 
Details on the long term conditions of the patients referred, their specified medication 
regimen, the medicine-related questions asked by the pharmacist at the follow-up 
consultation, any general patient feedback as recorded by the pharmacist, any reported 
adverse drug reactions (ADRs) and the advice given as a consequence, and any additional 
pharmaceutical or support services that was provided, were also collated and analysed. 
Hospital readmission rates and number of bed days 
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On 23th October 2015 the NHS numbers of all patients who participated in the electronic 
referral service between 1st July 2014 - 30th June 2015 were extracted by the hospital team 
and checked to see if they had been readmitted (all-cause admissions) post electronic 
referral and, if so, what specific dates they had been subsequently admitted and discharged 
on. Patients participating in the service after 30th June 2015 would not have had 
readmission data at 90 days post referral, hence the shorter analysis period was chosen. The 
data were anonymised and sent to an independent researcher (HN). The patient population 
was categorised into two groups: one received a community pharmacist follow-up 
consultation (completed referrals), and one did not (either accepted but not completed, 
referred (no action), and rejected referrals). The number of readmissions at 30, 60 and 90 
days post electronic referral was collated and number of bed days was calculated from 
length of hospital stays. 
Data analysis 
Quantitative data relating to the service activity was analysed using descriptive statistics and 
converted to percentages where appropriate to represent proportions. Text entered into 
free text boxes were collated, manually coded and then analysed. Readmission was defined 
as a stay of at least 12 hours. Association between the outcome of referrals (accepted, 
remain referred, completed, rejected) and type of pharmacy (e.g., supermarket, 
independent, etc.) were examined using a Chi-square test. A generalised estimating 
equation model was used to examine the association between readmission rate and 
whether patient received consultation or not from the community pharmacies.  Because 
repeated readmissions per patient at 30, 60 and 90 days are likely to be correlated, this 
model accounted for intra-patient correlation between the repeated data. Similarly, number 
of days admitted were analysed using linear model with a structured covariance matrix to 
account for repeated readmission data per patient. 
 
Discussion within the project team, together with hospital research ethics leads and on 
consultation of the NHS Health Research Authority guidance [18] identified the study 
components to be either audit or service evaluation and therefore did not require ethical 
approval. 
 
RESULTS 
Service Activity Data 
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A total of 2,029 hospital in-patients consented to participate in the Transfer of Care Service 
during the evaluative period, and were referred to their nominated community pharmacy. 
97.9% (n= 1986) of these referrals were generated by clinical technicians. The spread of 
these referrals over the 13 months are shown in Figure 1. This equated to approximately 
156 referrals being made each month to 207 community pharmacies across the North of 
Tyne, i.e., approximately 0.75 referrals per month per pharmacy. The rate of referrals 
fluctuated throughout the year but generally numbers increased, with the highest occurring 
in July 2015.  
 
Figure 1. The number of referrals made over the evaluative period. 
Community pharmacies were categorised according to Bush et al :  supermarket; multiple 
(200 outlets or more); large chain (more than 20 outlets but fewer than 200); small chain 
(20 outlets or fewer but more than 5); independent (5 outlets or fewer). [19] Table 1 shows 
how many referrals were received by each pharmacy type and whether these referrals were 
accepted, rejected or completed. Overall, Table 1 shows that outcomes of referrals varied 
significantly among the various types of pharmacies (p<0.001). This pattern was consistent 
for each outcome (accepted, remain referred, completed, rejected). Completion of referrals 
was not only highest for multiples, but also significantly higher than any other type of 
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pharmacy. Rejection was highest among small chain pharmacies, and was significantly 
higher than rejection rates from all other types of pharmacy. 
Table 1. The number of referrals received across the categories of community pharmacies (a-
d) and the subsequent outcomes of those referrals. ( ** denotes statistically significant 
difference at p<0.05 between pharmacy types) 
Outcome of 
referrals 
 
Type of Pharmacy 
Independent 
(a) 
n (% ) 
Multiples 
(b) 
n (%) 
Supermarket 
(c) 
n (%) 
Small Chain 
(d) 
n (%) 
Total  
n (%) 
P-value 
(a-d) 
Accepted 44 (8.8 ) a, c** 90 (8.5 ) b, c** 21 (16.5 ) c, d **   24 (7.0)  166  (8.2) 0.009 
Remain 
referred 
115 (22.9) 
a,b; a,d 
both** 
175 (16.6)
 
b,d** 
19 (15.0) 
c,d ** 24 (7.0 )  288 
(14.2) 
<0.001 
Completed 126 (25.1) a,b**; 
a,c** 
376 (35.6) 
b,c; b.d all** 
20 (15.8 )   75 (22.0)  619 
(30.5) 
<0.001 
Rejected 216 (43.2 ) a,d** 415 (39.3) 
b,c; b,d both** 
67 (52.6 ) 
c,d** 220 (64.1)  955 
(47.1) 
<0.001 
Total 501 (24.7) 1,057  (52.1) 128 (6.3 )  343 (16.9) 2,029 
(100.0 ) 
<0.001 
 
The decision to either accept or complete the referrals was largely carried out within 7 days 
of the community pharmacist receiving the referral (56.1 % and 66.2% respectively) as 
shown in Supplemental File 3. However, most rejections were made more than 7 days post-
discharge (66.9%). 
Of the total 2,029 referrals, 45.3% (n=955) were rejected by the community pharmacy. The 
389 rejections that occurred after December 2014 were accompanied with a reason, which 
are listed in Supplemental File 4. The most common reason for rejection was that the 
patient was uncontactable (35.5%, n=138), or that the patient was housebound (19.3%, 
n=75). However, after a change made to the PharmOutcomes template in June 2015 that 
removed ‘housebound’ as the default reason for rejecting a referral (see Supplemental File 
2), the rate of rejection for this reason dropped from 39% to 14%. 
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The age range of patients who agreed to receive a referral and the reasons for these 
referrals, of which there could be multiple reasons, were recorded by hospital pharmacy 
staff (Table 2). 
Table 2. The age of the patients and reasons for the referrals made by hospital pharmacy 
staff to community pharmacy during the evaluative period. (n=2,029) 
Characteristics of referrals  Number (%) 
Age of patient (yrs) 
<10 47 (2.3) 
11-19 14 (0.7) 
20-29 24 (1.2) 
30-39 65 (3.2) 
40-49 183 (9.0) 
50-59 270 (13.3) 
60-69 497 (24.5) 
>70 930 (45.8) 
Reason for referral 
MUR 663 (32.7) 
New medication(s) issued in hospital 365 (18.0) 
Compliance aid issue 168 (8.3) 
Changed dose(s) in hospital 148 (7.3) 
Stopped medication(s) in hospital 142 (7.0) 
Compliance issues 77 (3.8) 
MUR/New Medicines Service (NMS) 73 (3.6) 
Technique issue 57 (2.8) 
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Smoking cessation follow-up 43 (2.1) 
NMS 30 (1.5) 
Side effect issue 26 (1.3) 
Need for monitoring 24 (1.2) 
Check on well-being 16 (0.8) 
Repeat dispensing query 10 (0.5) 
Delivery service query 10 (0.5) 
Special formulation of medication 4 (0.2) 
No reason provided  601 (29.6) 
 
Only 30.5% (n=619) of referrals made resulted in a community pharmacist both “accepting” 
and recording the “completion” of the follow-up consultation. Table 3 details the long term 
condition or treatment of patients receiving a follow-up by a community pharmacist, the 
medication-related information they were provided with during the consultation, any advice 
on ADRs, and any additional pharmaceutical or support service that was also delivered. 
Table 3. The details of the referrals that were followed up by community pharmacists and 
recorded as completed. (n=619) 
Completed referral details Number of patients 
(%)  
Long term condition/treatment of patient 
Cardiovascular disease (CVD) 328 (53.0) 
Respiratory  126 (20.4) 
Diabetes  28 (4.6) 
CVD and diabetes  22 (3.5) 
Pain  11 (1.8) 
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Cancer  9 (1.4) 
Anticoagulant  8 (1.3) 
CVD and other 7 (1.1) 
Diabetes and other 3 (0.5) 
Hypertension  1 (0.2) 
None specified  76 (12.3) 
Information provided  
More information on medication(s)  557 (90.0) 
Dose check 543 (87.8) 
More information on condition 457 (73.8) 
Side effect check 521 (84.2) 
Advice provided on reported ADR  
Manageable and non-harmful – patient to continue 106 (17.1) 
Refer to GP 33 (5.4) 
Patient stopped taking medication 18 (2.9) 
Refer to hospital 5 (0.8) 
Not applicable 457 (73.8) 
Pharmaceutical/support service provided 
MUR 288 (46.6) 
NMS 241 (38.9) 
Home delivery service 138 (22.3) 
Compliance aid 79 (12.8) 
Repeat dispensing 53 (8.5) 
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Medicines reconciliation 28 (4.5) 
Smoking cessation 25 (4.0) 
Discussion 23 (3.7) 
Review of dosage form 17 (2.7) 
Review of compliance aid 13 (2.1) 
Influenza vaccination 12 (1.9) 
Medication administration record 7 (1.1) 
Large print labels 7 (1.1) 
Easy open tops 6 (1.0) 
Healthy living advice 6 (1.0) 
Appliance use review 1 (0.2) 
None  331 (53.4) 
 
The majority of patients that were followed-up were those with a cardiovascular or 
respiratory disease. Most patients received information from the community pharmacist on 
their medication (90.0%, n=557), doses (87.8%, n=543), occurrence of side effects (84.2%, 
n=521) and their conditions (73.8%, n=457). Most patients (73.8%, n=457) did not report an 
ADR to the community pharmacist during the consultation. However, of those who did, 
17.1% (n=106) were considered manageable and non-harmful to the patient, and thus the 
patients were advised to continue taking their medication as prescribed. Most patients did 
not receive any additional pharmaceutical or support service (53.4%, n=331), but many 
received a Medicines Use Review (46.6%, n=288) and/or were enrolled on the New 
Medicines Service (38.9%, n=241). Of these patients who were provided with a follow-up 
consultation, 40.4% (n=250) provided feedback via the pharmacist. Just over half of these 
patients reported that the information was a good reconfirmation of the information 
provided within hospital and at discharge (52.4%, n=131); 90 (36%) of the patients 
expressed their appreciation for the contact with the community pharmacist, and the 
usefulness of their advice and/or service provided through this initiative; a small number 
(4.8%, n=12) refused or were reluctant to receive any form of follow-up consultation by the 
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community pharmacist in the future. In the remainder of cases (6.8%, n=17), pharmacists 
recorded how the patient was either too ill to be spoken to or that they consulted with their 
carer instead. 
Hospital readmissions and number of bed days 
There were a total of 1,386 hospital patients who received electronic referrals to community 
pharmacy during the period 1st July 2014 - 30th June 2015; of these 501 (36.1%) had a record 
of receiving a follow-up consultation by a community pharmacist (‘completed’ referral) 
(Table 4). 607 (43.8%) of the remaining 885 patients are unlikely to have received a follow-
up community pharmacist consultation as the status of their referral on the 
PharmOutcomes system remained either ‘referred (no action)’, ‘accepted’ but not 
completed.  A total of 278 (20.0%) were ‘rejected’ by the community pharmacist. Table 4 
displays the readmissions rates and number of bed days of patients who either received or 
did not receive a follow-up community pharmacist consultation. The odds of readmission 
was found to be significantly higher amongst those who did not receive a follow-up 
consultation from the community pharmacy. This result is consistent across the three 
readmission time points (30, 60 and 90 days). Over the same time period, the 30 day 
readmission rate was 13.2%, which is higher than that of the group of patients who received the 
community pharmacist follow-up and lower than that of the patients who did not receive the 
community pharmacist follow-up. Among patients readmitted, the average duration of hospital 
stay at any time point (30, 60 or 90 days) was at least 5 days less for those who received 
consultation. 
Table 4. The readmissions and number of bed days of patients who received a follow-up 
community pharmacist consultation and of patients who did not. 
Patient cohort Number of readmissions post electronic 
referral at  
Number of bed days for 
readmitted patients at 
0-30 days 
n (%) 
31-60 days 
n (%) 
61-90 days 
n (%) 
30 days 
mean ± 
SD 
60 days 
mean ± 
SD 
90 
days 
mean ± 
SD 
Received a CP 
consultation (n= 501) 
 
29 (5.8) 17 (3.4) 18 (3.6) 7.2±1.0  7.2 ± 
6.4 
 
7.3 ± 
6.7  
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Did not receive CP 
consultation (n= 885) 
142 (16.0) 84 (9.5) 83 (9.4) 13.1 ± 
17.4  
13.7 ±  
19.2 
12.5 ± 
16.6 
Odds ratio and 95% 3.1 3.0 2.8    
Confidence Intervals 
(N=1386) 
(2.1, 4.7) (1.8, 5.1) (1.6, 4.7)    
Mean differences and 
95% Confidence Intervals 
(N =373) 
   -5.8 
(-12.7, 
1.0) 
-6.5 
(-15.4, 
2.4) 
-5.2 
(-13.9, 
3.5) 
 
 
DISCUSSION 
This Transfer of Care Service addressed a recognised patient need as they transition 
between care settings. Our findings show how an electronic solution, in this case 
PharmOutcomes, can be employed to facilitate the transfer of information between hospital 
and community pharmacy teams to improve the coordination of care as patients transfer 
between care settings. We have provided a detailed description of how this specific 
electronic referral process worked in practice, so as to help inform future service designers 
and implementers. We also provide information of the ongoing changes made during the 
evaluation period which aimed to increase rates of referrals, completion and reduce 
rejections. Additional changes have and are being made in response to continuing 
evaluation of the service delivery and activity. We found that community pharmacy 
engagment, through linking with Local Pharmacy Committees and Regional Managers of 
large multiples, along with close working relationships with the developers of the eReferral 
platform, were key to designing, adapting and delivering a successful process. 
Over the 13 month evaluative period, 2,029 patients were referred to their nominated 
community pharmacy. This is a modest number of referrals considering there was no 
eligibility criteria to restrict activity. Ramsbottom et al [20] also report a very small 
proportion of elgible in-patients (3.2% of over 10,000 potential patients) were identified to 
receive referrals to community pharmacists for domiciliary MURs. The main reasons put 
forward by the authors for these low referral rates were that the service was new and not 
embedded into practice, hospital staff had other competing priorities  and the patients’ 
poor health were reported as barriers to making referrals. [20] Further qualitative data 
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collection from hospital pharmacy staff could explore the reasons for low referral rates in 
our study and aid in the design of solutions to increase activity. Qualitative data from 
community pharmacists would also explore the low completion rate and investigate the 
faciliators and barriers to the embedding of this service into normal practice. The 
Normalisation Process Model, as proposed by May [21] would be an appropriate theoretical 
framework to evaluate the process and context of implementation. 
Unfortunately, we did not record the details of all patients who were approached by 
hospital pharmacy staff and offered an electronic referral. It would be interesting to further 
investigate why patients decided to refuse these referrals. A recent study found that 32% of 
elderly patients eligible to receive a visit from a pharmacist post hospital discharge refused. 
The most common reasons stated in this study were the lack of perceived benefit of the 
interaction with a community pharmacist and preference to see their GP. [20] Yu et al [22] 
also found that once their patient population was made aware of the availability and 
benefits of a post discharge pharmacist home medicines review, the majority of patients 
were willing to participate. [22]  
Most referrals were sent to multiple chain pharmacies (52.1%, n=1,057) as nominated by in-
patients. Multiple chain pharmacies made up 50.2% of the total number of pharmacies in 
the area (104 out of 207). This category of pharmacy also had the highest completion rate of 
eReferrals, significantly higher than all other pharmacy types (35.6%, n=376). The 
supermarket pharmacies received the least number of eReferrals (6.3%, n=128) and also 
had the lowest completion rate (15.8%, n=20), which was statistically lower than all other 
pharmacy types. Further investigation is needed to explore the motivators and barriers of 
pharmacists to accept/refuse eReferrals and whether the type of pharmacy at which the 
pharmacist was based influenced their decision. Work carried out by Jacobs et al [23, 24] 
may provide a framework in evaluating if and how the culture in various community 
pharmacy organisations impact their performance in pharmaceutical services. Another 
evaluation of a pharmaceutical service utilising PharmOutcomes for routine data collection 
suggested that low recorded completion rates on this IT platform may have been due to the 
community pharmacists not logging onto the system and documenting their actions. [25] In 
which case the referrals that are listed as ‘remain referred’ or ‘accepted’ may have actually 
been formally completed or rejected. Most eReferrals were ‘accepted’ or ‘completed’ within 
7 days of receipt, whereas most rejections occurred after 7 days. It is important to 
understand this time lag and whether the delay was due to events not under the community 
pharmacist control, e.g., multiple attempts to contact the patient. The most highly reported 
reasons for rejections of referrals by the community pharmacists was that the patient was 
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uncontactable (35.1%, n=138). Specific reasons for this needs to be explored to understand 
if this is an issue with the service design and delivery, e.g. patients may not answer 
unidentifiable numbers; patients may provide erroneous contact details instead of refusing 
a referral, etc. A considerably large number of pharmacist rejections in our study were due 
to the patients being housebound (19.3%, n=75), however, it was observed that rates of 
patients registered as ‘housebound’ dropped from 39% of rejections to 14%, after the 
change was made on the electronic template. Where the referral had been sent to a 
pharmacy which was not routinely used by the patient (12.4%, n=48), again further 
understanding is required to check if this is something that could be further improved in the 
design of the service or patient deflection. It is possible that patients newly prescribed 
medicines who were not taking medicines prior to admission to hospital (e.g. post MI) and 
therefore not known by the community pharmacy had their referral rejected when their 
need for support was greatest. Further detailed analysis is therefore warranted.  
The majority of patients that consented for an electronic referral were elderly (60 years and 
over, 70.3%, n=1,427) and the most common reasons that a referral was made by hospital 
staff was for medication–related problems (MUR; initation/cessation/changed medicine or 
dose in hospital; medibox issue; medication compliance issue). Those patients who 
ultimately received a follow-up consultation from a community pharmacist were those with 
reported cardiovascular disease (53.0%, n=328) or a respiratory condition (20.4%, n=126). 
This may reflect the areas in the hospital being targeted by clinical pharmacy staff, however, 
empirical research is required to investiagte this. These patient demographics may be useful 
to consider in defining elegibility criteria for the referral of future patients. Within the 
follow-up consultation pharmacists had the opportunity to provide information on 
medication, dosing, medical condition, side effects/ADRs and their subsequent 
management. Most of the patients were not provided with an additional pharmaceutical or 
support service (53.4%, n=331), but 46.6% (n=288) of patients received an MUR and/or 
initiated the New Medicines Service (38.9%, n=241). 
Routine data collection does not include a measure that meets any Economic, Clinical or 
Humansitic Outcomes model [26], this means that the impact and value of the intervention 
cannot be understood. Despite the tailoring of the community pharmacist follow-up 
consultation to the patient’s expressed need, no subsequent outcome data associated with 
the tailored pharmaceutical care and/or service is routinely recorded to demonstrate the 
effect. Where MURs were performed or NMS intiated, there is no inclusion of the actions 
and recommendations of the community pharmacist within routine data collection on 
PharmOutcomes. The information for these two specific services have their own separate 
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documentation and recording process. Inclusion of this information with the eReferral 
service data may provide further detail on the impact of the community pharmacist 
intervention on patient outcomes, e.g. medication or condition related issues and advice, 
referrals onto GPs for monitoring or consultation. Future evaluations should aim to identify 
a specific parameter that can be used directly or as a proxy to measure economic, 
humanistic or clinical outcomes. 
 Of the relatively small proportion of patients who provided ad hoc feedback via the 
pharmacist about the service, just over half felt that the information received reconfirmed 
what they had been previously told in hospital; some patients appreciated this and found it 
useful. Our study found that those patients who received a follow-up community 
pharmacist consultation as a result of a hospital eReferral demonstrated statistically lower 
readmissions and shorter hospital stays as a result of any readmission. However, further 
critical analysis of this positive association, e.g. explore the individual reasons for 
readmissions, use of other healthcare services, etc., is required to substantiate a causal link. 
The service aimed to improve the transition of the patient between care settings which 
would be best tested via a randomised control trial. However, prior to carrying this out a 
feasibility study is required. This work would determine how best to design the future trial 
and identify primary and secondary outcomes that would be feasible to collect and allow 
assessment of effectiveness. 
The strengths of this study is that it specifically describes the implementation and operation 
of an electronic referral process from hospital to community pharmacy. We have 
highlighted possible areas for further improvement, but feel that the lessons learnt so far 
are both relevant and valuable to those considering the implementation of a similar process. 
The marrying of service activity with the developmental changes also provides context to 
the critical reader in understanding context and to the service planner of the continual 
monitoring and malleability of the service. 
A weakness of this evaluation is that there is no test for fidelity of service delivery and 
implementation. An investigation of how well hospital and community pharmacy staff adher 
to the recommended process might provide further insights into the relatively low referral 
and completion rates that have been recorded on PharmOutcomes.  
The systematic review by Hesselink at al [7] found that interventions that exhibited specific 
components, e.g. medicines reconciliation, showed statistically significant effects in favour 
of the intervention, i.e. reconciliation reducing the percentage of unreconciled medication 
after discharge. [7] A future clinical study should ensure service data collection is 
 19 
 
appropriate to allow assessment of intervention effect. The detailed intervention 
description provided here will allow better understanding of facilitators and barriers to 
outcomes that will be recorded. This study also highlights a deficiency of the intervention 
itself: the lack of comprehensive discharge information routinely accompanying the referral. 
Another recent systematic review concluded that those interventions that aimed to identify 
and rectify drug-related problems showed the most statistically significant benefit. [8] 
However to facilitate this there needs to be sufficient medication-related information 
transferred between healthcare settings. With the recent announcement that Summary 
Care Records, an electronic patient record derived from patients’ GP records will be 
provided more widely to community pharmacists, [25] it is anticipated that the information 
gradient between primary and secondary care will be reduced. 
CONCLUSIONS 
Patients in hospitals can be electronically referred to their nominated community pharmacy 
upon discharge from hospital in order to receive a follow-up consultation tailored to their 
specific need. We have shown that multiple stakeholders from the hospital, community 
pharmacy organisations and IT system developers working collaboratively could design and 
implement an electronic eReferral service from hospital to community pharmacy. Electronic 
referral non-completion rates during the study period appear to be high. This may be due to 
this period encompassing the launching and embedding of such a pioneering service. Early 
indications are that patients referred from hospital, who receive a follow-up consultation 
from their community pharmacist may have lower rates of readmission and shorter hospital 
stays. 
 A feasibility study will identify how and which outcomes will allow effectiveness of this 
intervention to be measured.  
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